Except for idecabtagene vicleucel (AbecmaTM), which targets B cell maturation antigen (BCMA) for use in r/r multiple myeloma [1], the remaining FDA-approved CAR-T cell therapies all target CD19 and are approved for treatment of various malignancies of lymphoid lineage including B-ALL, diffuse large B-cell (DLBCL), follicular, and mantle cell lymphoma [2,3,4,5]. The gene discussed is TNFRSF17; the disease is diffuse large B-cell lymphoma.